Someone else already paid for the growth: management describes an outside party bearing the cost, risk, or work that exp
The model's full reasoning — Q2 2017 call → NOWe need to determine if management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the payoff mostly ahead. Look for concrete examples: partners funding, building, staffing, etc. The transcript mentions several deals: BMS licensing (BIIB092), Remedy Pharmaceuticals acquisition (BIIB093), collaboration with Eisai, Ionis, Penn, Brammer Bio, Samsung Bioepis JV. But these are mostly acquisitions or collaborations where Biogen is paying or investing. The question is about outside parties bearing cost/risk/work to expand Biogen's business. For example, the JV with Samsung Bioepis: Biogen has a stake, but is it outside party bearing cost? The JV is a separate entity, but Biogen is investing. The transcript says "our biosimilar business" and "our JV, Samsung Bioepis" - but it's a joint venture, so both parties invest. Not clearly outside bearing cost. Also, the value-based contracts: those are pilots, not yet broad. The EAP (expanded access program) for SPINRAZA: that's Biogen providing free drug, not outside. The newborn screening: states passing bills, but that's not directly expanding Biogen's business in a way that outside party bears cost. The transcript mentions "we are working with patients, physicians and payers to expand access" - that's Biogen's effort. The question asks if an outside party is already bearing cost/risk/work of expanding the company's business. There is mention of "our collaboration partner Eisai" progressing a study, but that's a partnership where both share. Also, "in collaboration with Ionis" - again, joint. The key is whether management conveys that someone else is spending their own money to expand Biogen's reach. The transcript does not clearly describe such a phenomenon. The deals are acquisitions or licensing where Biogen pays. The JV is a shared investment. The value-based contracts are pilots, not yet broad. The EAP is Biogen's own program. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| MGNX | MacroGenics, Inc. | Q3 2016 | 2016-11-02 | D |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
INST · Q4 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the Paychex partnership as a white-label reseller arrangement where Paychex is already bearing the cost, risk, and work of expanding Instructure’s business by offering Bridge Learn to its 0.5 million customers (6 million users) using its own salesforce and customer base — a real, underway effort since the partnership was entered into and integration is already in progress. Management explicitly states Paychex owns the customers and will sell the product, while Instructure is only powering the backend, and the resulting revenue is still mostly ahead (they are optimistic about significant success by year-end). This matches 100% of the required criteria.
PLAB · Q2 2017 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing the DNP JV as an outside party already bearing the bulk of the expansion costs and risks for the new China facility (the $160 million Xiamen site, previously announced as a company-led greenfield build last August). Peter Kirlin notes they will "utilize all cash held in Taiwan and greater reduced to risk of ramping of our new factory in China," while Sean Smith confirms they are "sharing that total investment of 160 million as we in essence have a 50-50 partnership, however we will consolidate it" and will "share equitably the startup cost.
YUM · Q2 2018 → YESThe question is about whether management describes an outside party already bearing the cost, risk, or work of expanding the company's business, with the effort real and underway now, but the resultin...YES The transcript shows management describing real, ongoing outside efforts by franchisees and partners already bearing the cost, risk, and work of expansion. Franchisees are actively spending their own capital to open units (e.g., 482 net new units YTD vs. 317 last year; KFC opening nearly 200 2Q units; Pizza Hut 6% net new unit growth; Taco Bell 9 international units), with the company 97% franchised and on track for 98%. These efforts are already in motion and contributing to current results, while management highlights acceleration and future ramp (e.g.